Genafor Beta Software Services
In this section we present software that has gone through initial testing in the developer lab which is the basis for the publication. This software has not yet been submitted to routine clinical testing. If you require software that has been submitted to routine clinical testing please turn to the software offers under the tab "Services".
|A therapy prediction service for HIV based on previous drug treatments.
|The entry of the human immunodeficiency virus (HIV) into human
cells is conditioned by successful binding of the virus to one of the
cell-surface chemokine coreceptors CCR5 or CXCR4. The binding site of
the coreceptor is partially situated on the third variable region
(V3) of gp120 protein. The capacity of the virus to bind to CCR5 only
(R5 virus), to CCR5 and CXCR4 alternately (dual virus) or to CXCR4
only (X4 virus) - termed viral tropism - is determined predominantly by the sequence and
structure of the V3.
In the early, asymptomatic stages of infection mainly R5 viruses are
observed, progression to AIDS is often correlated with the emergence
of X4 viruses. Also, several CCR5 inhibitors are currently
available for patient treatment. Relation of viral tropism to disease
progression and new therapies targeting R5 viruses call for efficient
monitoring of coreceptor usage and for a better understanding of its